Author

M. Karam

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. Cao· 1 shared A. D'Amico· 1 shared A. Malina· 1 shared A. Marechal· 1 shared A. Orthwein· 1 shared A. Samiei· 1 shared B. Djerir· 1 shared C. Dove· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Cao

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

The Fatty Acid Binding Protein Family Represents a Novel Target in Multiple Myeloma

M. Farrell, H. Fairfield, M. Karam, A. D'Amico, C. S. Murphy, C. Falank, R. S. Pistofidi, A. Cao, C. R. Marinac, J. A. Dragon, L. McGuinness, C. G. Gartner, R. D. Iorio, E. Jachimowicz, V. DeMambro, , M. R. Reagan

This paper identifies the fatty acid binding protein (FABP) family as a novel therapeutic target in multiple myeloma, showing that FABP inhibition reduces tumor growth and alters key cellular processes.

eLife · Mar 7, 2023Peer-reviewedCancer Biology

FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice.

A. Orthwein, S. Findlay, J. Heath, V. Luo, A. Malina, Z. Li, A. Samiei, E. S. Cheyou, M. Karam, H. Bagci, D. Rahat, D. Grapton, E. G. Lavoie, C. Dove, H. Khaled, , H. Kuasne

This study identifies FAM35A as a novel REV7 effector that promotes NHEJ and restricts HR by limiting DNA end resection at DSBs.

bioRxiv · Jul 11, 2018Cancer Biology